We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Bioequivalence Study of Telmisartan Between Telmisartan 80 mg/Amlodipine 5 mg FDC Tablet and Telmisartan 80 mg Tab and Amlodipine 5 mg Tab Concomitant Use

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01344629
First Posted: April 29, 2011
Last Update Posted: March 28, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Boehringer Ingelheim
  Purpose
To investigate the bioequivalence of telmisartan administrated in two different ways: both in telmisartan 80 mg/amlodipine 5 mg fixed-dose combination tablets (T) and as telmisartan 80 mg tablet and amlodipine 5 mg tablets (R) in concomitant use

Condition Intervention Phase
Healthy Drug: Telmisartan/Amlodipin FDC Drug: Telmisartan Drug: Amlodipin Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Official Title: Bioequivalence of Telmisartan Administrated in Two Different Ways: Both in Telmisartan 80 mg/Amlodipine 5 mg Fixed-dose Combination Tablet and Telmisartan 80 mg Tablet and Amlodipine 5mg Tablet in Concomitant Use in Healthy Male Volunteers. (an Open-label, Randomized, Single-dose, Four-period Replicated Crossover Study)

Resource links provided by NLM:


Further study details as provided by Boehringer Ingelheim:

Primary Outcome Measures:
  • AUC0-tz [ Time Frame: Serial pharmacokinetic blood samples collected before drug administration, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours after drug administration ]
    Area under the concentration-time curve of Telmisartan in plasma over the time interval from 0 to the time of the last quantifiable data point

  • Cmax [ Time Frame: Serial pharmacokinetic blood samples collected before drug administration, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours after drug administration ]
    maximum measured concentration of Telmisartan in plasma


Secondary Outcome Measures:
  • AUC0-∞ [ Time Frame: Serial pharmacokinetic blood samples collected before drug administration, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours after drug administration ]
    area under the concentration-time curve of Telmisartan in plasma over the time interval from 0 extrapolated to infinity

  • Tmax [ Time Frame: Serial pharmacokinetic blood samples collected before drug administration, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours after drug administration ]
    time from dosing to the maximum concentration of Telmisartan in plasma

  • λz [ Time Frame: Serial pharmacokinetic blood samples collected before drug administration, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours after drug administration ]
    terminal rate constant of Telmisartan in plasma

  • t1/2 [ Time Frame: Serial pharmacokinetic blood samples collected before drug administration, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours after drug administration ]
    terminal half-life of Telmisartan in plasma

  • MRTpo [ Time Frame: Serial pharmacokinetic blood samples collected before drug administration, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48 and 72 hours after drug administration ]
    mean residence time of Telmisartan in the body after oral administration


Enrollment: 64
Study Start Date: April 2011
Primary Completion Date: July 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Telmisartan80mg/Amlodipin5mg FDC
single-dose, four-period replicated crossover design
Drug: Telmisartan/Amlodipin FDC
Telmisartan80mg/Amlodipin5mg FDC
Experimental: Telmisartan80mgtab + Amlodipin5mg tab
single-dose, four-period replicated crossover design
Drug: Telmisartan
Telmisartan 80 mg tablet
Drug: Amlodipin
Amlodipin 5mg tablet

Detailed Description:
Purpose:
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years to 35 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion criteria:

  1. Without any clinically significant findings and complications on the basis of a complete medical history, including the physical examination, vital signs (blood pressure, pulse rate, body temperature), 12-lead electrocardiograms (ECGs), clinical laboratory tests
  2. Age: =20 and =35 years
  3. Body weight: =50 kg and =80 kg
  4. Body mass index (BMI): =18.0 and =25.0 kg/m2

Exclusion criteria:

  1. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological, or hormonal disorders
  2. Diseases of the central nervous system (such as epilepsy) or psychiatric or neurological disorders
  3. Chronic or relevant acute infections
  4. Any clinical relevant findings in laboratory test results deviating from normal
  5. A positive result in hepatitis B surface antigen (HBsAg), anti-hepatitis C virus (HCV) antibodies, a syphilis test, or an human immunodeficiency virus (HIV) test
  6. History of surgery of the gastrointestinal tract (except appendectomy)
  7. History of relevant orthostatic hypotension, fainting spells, or blackouts
  8. Known hypersensitivity to any component of the formulation (telmisartan and amlodipine), to any other angiotensin receptor blocker, or to any other dihydropyridine calcium channel blocker compound
  9. Intake of drugs with a long half-life (=24 hours) within at least 1 month or less than 10 half-lives of the respective drug before drug administration
  10. Intake of drugs which might reasonably influence the results of the trial on the basis of the knowledge at the time of protocol preparation within 7 days before drug administration
  11. Participation in another trial with an investigational drug within 1 months or less than 10 times of half-lives of the investigational products before drug administration
  12. Smoker (=20 cigarettes/day)
  13. Alcohol abuse (60 g or more ethanol/day: e.g., 3 middle-sized bottles of beer, 3 gous [equivalent to 540 mL] of sake)
  14. Drug abuse
  15. Blood donation (more than 100 mL within 4 weeks before drug administration)
  16. Excessive physical activities (ex. Marathon etc) within 1 week before drug administration
  17. Intake of alcohol within 2 days before drug administration
  18. Inability to comply with dietary regimen of the study site
  19. Inability to refrain from smoking during trial days
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01344629


Locations
Japan
1235.28.001 Boehringer Ingelheim Investigational Site
Kumamoto, Kumamoto, Japan
Sponsors and Collaborators
Boehringer Ingelheim
Investigators
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
  More Information

Responsible Party: Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT01344629     History of Changes
Other Study ID Numbers: 1235.28
First Submitted: April 26, 2011
First Posted: April 29, 2011
Results First Submitted: July 10, 2012
Results First Posted: August 27, 2012
Last Update Posted: March 28, 2014
Last Verified: February 2014

Additional relevant MeSH terms:
Telmisartan
Amlodipine
Antihypertensive Agents
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Vasodilator Agents
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists


To Top